Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-term Injection of Recombinant Human Endostatin Plus EGFR-TKI as a Treatment of EGFR Mutation-positive Advanced Non-small Cell Lung Cancer

NCT03008109 is registered in ClinicalTrials.gov with Zaiwen Fan as lead sponsor.

NCT NCT03008109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03008109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-term Injection of Recombinant Human Endostatin Plus EGFR-TKI as a Treatment of EGFR Mutation-positive Advanced Non-small Cell Lung Cancer
Lead sponsor
Zaiwen Fan
Phase
Phase 3
Overall status
Unknown status
Start date
February 28, 2017
Completion date
November 30, 2018
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, lung cancer, nonsmall cell